These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 23293059)

  • 41. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induced pluripotent stem cells (iPSCs): the emergence of a new champion in stem cell technology-driven biomedical applications.
    Das AK; Pal R
    J Tissue Eng Regen Med; 2010 Aug; 4(6):413-21. PubMed ID: 20084623
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of induced pluripotent stem cells in drug development.
    Inoue H; Yamanaka S
    Clin Pharmacol Ther; 2011 May; 89(5):655-61. PubMed ID: 21430656
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Endless possibilities: stem cells and the vision for toxicology testing in the 21st century.
    Chapin RE; Stedman DB
    Toxicol Sci; 2009 Nov; 112(1):17-22. PubMed ID: 19703945
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human stem cells for modeling neurological disorders: accelerating the drug discovery pipeline.
    Crook JM; Kobayashi NR
    J Cell Biochem; 2008 Dec; 105(6):1361-6. PubMed ID: 18980214
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Embryonic stem cells and the next generation of developmental toxicity testing.
    Kugler J; Huhse B; Tralau T; Luch A
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):833-841. PubMed ID: 28675072
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A high-throughput screen for teratogens using human pluripotent stem cells.
    Kameoka S; Babiarz J; Kolaja K; Chiao E
    Toxicol Sci; 2014 Jan; 137(1):76-90. PubMed ID: 24154490
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evolution of induced pluripotent stem cell technology.
    Zhou H; Ding S
    Curr Opin Hematol; 2010 Jul; 17(4):276-80. PubMed ID: 20442654
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neurotoxicity of active compounds--establishment of hESC-lines and proteomics technologies for human embryo- and neurotoxicity screening and biomarker identification.
    Klemm M; Schrattenholz A
    ALTEX; 2004; 21 Suppl 3():41-8. PubMed ID: 15057407
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Toxicology testing in drug discovery and development.
    Dorato MA; Buckley LA
    Curr Protoc Toxicol; 2007 Feb; Chapter 19():Unit19.1. PubMed ID: 23045141
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Translational prospects for human induced pluripotent stem cells.
    Csete M
    Regen Med; 2010 Jul; 5(4):509-19. PubMed ID: 20632855
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human pluripotent stem cells for genetic disease modeling and drug screening.
    Gauthier M; Maury Y; Peschanski M; Martinat C
    Regen Med; 2011 Sep; 6(5):607-22. PubMed ID: 21916596
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Toward preclinical predictive drug testing for metabolism and hepatotoxicity by using in vitro models derived from human embryonic stem cells and human cell lines - a report on the Vitrocellomics EU-project.
    Mandenius CF; Andersson TB; Alves PM; Batzl-Hartmann C; Björquist P; Carrondo MJ; Chesne C; Coecke S; Edsbagge J; Fredriksson JM; Gerlach JC; Heinzle E; Ingelman-Sundberg M; Johansson I; Küppers-Munther B; Müller-Vieira U; Noor F; Zeilinger K
    Altern Lab Anim; 2011 May; 39(2):147-71. PubMed ID: 21639679
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The application of engineered liver tissues for novel drug discovery.
    Lin C; Ballinger KR; Khetani SR
    Expert Opin Drug Discov; 2015 May; 10(5):519-40. PubMed ID: 25840592
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug discovery through stem cell-based organoid models.
    Ranga A; Gjorevski N; Lutolf MP
    Adv Drug Deliv Rev; 2014 Apr; 69-70():19-28. PubMed ID: 24582599
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The potential of embryonic stem cells combined with -omics technologies as model systems for toxicology.
    Winkler J; Sotiriadou I; Chen S; Hescheler J; Sachinidis A
    Curr Med Chem; 2009; 16(36):4814-27. PubMed ID: 19929785
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Advances in the development and use of human tissue-based techniques for drug toxicity testing.
    Clotworthy M; Archibald K
    Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1155-69. PubMed ID: 23687950
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases.
    Hung SSC; Khan S; Lo CY; Hewitt AW; Wong RCB
    Pharmacol Ther; 2017 Sep; 177():32-43. PubMed ID: 28223228
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In Vitro Developmental Toxicology Screens: A Report on the Progress of the Methodology and Future Applications.
    Zhang C; Ball J; Panzica-Kelly J; Augustine-Rauch K
    Chem Res Toxicol; 2016 Apr; 29(4):534-44. PubMed ID: 26766213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.